CC
MYGN icon

Centiva Capital’s Myriad Genetics MYGN Stock Holding History

Centiva Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,169
Closed -$271K – 2070
2023
Q4 		$271K Buy
+14,169
New +$245K 0.01% 1259
2023
Q2 		– Sell
-10,402
Closed -$242K – 1861
2023
Q1 		$242K Buy
+10,402
New +$211K 0.01% 1150

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Centiva Capital's MYGN Position: Q1 2024 in Review

Centiva Capital sold out of Myriad Genetics (MYGN) in Q1 2024, closing a stake of 14,169 shares — an estimated $271K sold.

Centiva Capital first reported a position in MYGN in Q1 2023 and held it in 2 quarters. The position peaked at $271K in Q4 2023. 186 funds tracked by Wall St. Rank hold MYGN as of Q1 2024.

  • Centiva Capital reported no remaining Myriad Genetics position as of Q1 2024 after selling out during the quarter.
  • Centiva Capital sold 14,169 Myriad Genetics shares in Q1 2024, an estimated $271K.
  • Centiva Capital first reported a position in Myriad Genetics in Q1 2023 and held it in 2 quarters.
  • Centiva Capital's Myriad Genetics position peaked at $271K in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2024.

Based on Centiva Capital's 13F filing for Q1 2024, filed 15 May 2024.